Galapagos(GLPGF)
2800 MECHELEN, BelgiumBiotechnology
Focus: Galapagos is a publicly-traded biotech company headquartered in Belgium specializing in drug and antibody therapy discovery across immunology, rare diseases, respiratory, oncology, and nephrology. The company operates as a mid-cap biotech with a diversified pipeline but currently no approved marketed products.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Galapagos
AI assessmentNot HiringNo open roles listed right now. Follow Galapagos to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
JAK inhibitor treatment
Colitis, UlcerativeClinical Trials (1)
NCT05456412JAK Inhibition in Ulcerative Colitis
N/AHelp build intelligence for Galapagos
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.